Prescription drug · ANDA
Etoposide NDC 0143-9511
Etoposide 20 mg/mL · Injection · Intravenous · Hikma Pharmaceuticals USA Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 0143-9511-01 | 00143951101 | 1 VIAL in 1 BOX, UNIT-DOSE (0143-9511-01) / 25 mL in 1 VIALMarketed from Oct 23, 2017 |
How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Etoposide
- Generic name (nonproprietary)
- etoposide
- Active ingredients
- Etoposide — 20 mg/mL
- Dosage form
- Injection
- Route
- Intravenous
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 074290
- Marketing start
- Listing expires
- Other FDA classes
- Topoisomerase Inhibitors (Mechanism)
- Identifiers
- Product ID 0143-9511_15cf77cf-4207-463d-b6ef-16163db5afb9SPL ID 15cf77cf-4207-463d-b6ef-16163db5afb9SPL set ID 6dfedeff-a807-4405-a482-2f7109ad31c9RxCUI 310248UNII 6PLQ3CP4P3
- Pharmacologic class
- Topoisomerase Inhibitor
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- Administration
Drug administration (CPT 96360–96549)
When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.
- NDC on a medical claim
N400143951101followed by a unit qualifier and the quantityPackage 00143-9511-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective . This label includes a boxed warning.
Indications (excerpt from the label)
INDICATIONS AND USAGE Etoposide Injection, USP is indicated in the management of the following neoplasms: Refractory Testicular Tumors Etoposide injection in combination therapy with other approved chemotherapeutic agents in patients with refractory testicular tumors who have already received appropriate surgical, chemotherapeutic, and radiotherapeutic therapy. Small Cell Lung Cancer Etoposide injection and/or capsules in combination with other approved chemotherapeutic agents as first line treatment in patients with small cell lung cancer.
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 074290
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Etoposide | Etoposide 20 mg/mL | InjectionIntravenous | Hikma Pharmaceuticals USA Inc. | 0143-9510 |
| Etoposide | Etoposide 20 mg/mL | InjectionIntravenous | Hikma Pharmaceuticals USA Inc. | 0143-9512 |
| Etoposide | Etoposide 20 mg/mL | InjectionIntravenous | Hikma Pharmaceuticals USA Inc. | 0143-9376 |